Year-to-date money raised in public, private and other financings of biopharma companies.

Biopharma money raised to-date and by quarter in 2019, including public, private and other financings.

Follow-ons completed by biopharma companies, including: Baudax, Cel-Sci, Compugen, Hoth, Kala, Seelos, Tiziana Life Sciences, Zogenix.

Private placements and other private financings of public biopharma companies, including: AB Science, Akari, Armata, Aytu, Baudax, Bellerophon, Biocurepharm, Brainstorm, Bridgebio, Cocrystal, Cytodyn, Emmaus Life Sciences, Enlivex, Equillium, Ethismos Research, Eton, Eyenovia, Helix, Hemostemix, IMV, Isofol Medical, Lattice, Marker, Moberg, Novan, Oncology Venture, Oncoquest, Pacylex, Plx, Predictive Oncology, Propanc, Protalix, Redx, Rockwell Medical, Theravance, Titan, Tonix, Unum, Vaccinex, Vaxart, Vaxil Bio, Verastem, Verrica, Vistagen, Xortx, Zosano.

Venture capital and other private financings of private biopharma companies, including: Abbisko, Advanced Biodesign, Affinia, Akouos, AM-Pharma, Amunix, Apexigen, Biosight, Castle Creek, Cinclus, Circle, Clarus, Design, Elevatebio, Eureka, Evonetix, Exuma, Harbour Biomed, Immunocore, Kallyope, Keros, Kymera, Lipidio, Nanjing Iaso, Numab, Nurix, Oncoone R&D, Onethree, Pliant, Polyprox, Primmune, Recode, Redpin, Regenacy, Sigilon, Silverback, Sutrovax, Svenska Vaccinfabriken Produktion, Syndivia, Tikomed, Xilio, Zucara.

Triggered milestone payments disclosed by biopharma companies, including: Abbvie, AC Immune, Boehringer Ingelheim, Cytomx, Eli Lilly, Oxford.

These graphs compare the performance of the biotech stocks for all of 2020 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.

The top 10 biopharma stock gainers and losers for the week.